Illumina Inc. (ILMN) Shares Up 2.1%
Shares of Illumina Inc. (NASDAQ:ILMN) shot up 2.1% on Friday . The company traded as high as $174.00 and last traded at $173.09, with a volume of 531,490 shares. The stock had previously closed at $169.48.
A number of brokerages have recently weighed in on ILMN. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. CL King cut Illumina from a “buy” rating to a “neutral” rating in a research report on Monday. Piper Jaffray Cos. reiterated an “overweight” rating and set a $161.00 price target on shares of Illumina in a research report on Friday, July 15th. Vetr cut Illumina from a “buy” rating to a “sell” rating and set a $142.96 price target on the stock. in a research report on Tuesday, July 26th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $140.00 price target (down from $160.00) on shares of Illumina in a research report on Wednesday, May 4th. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $165.65.
The firm has a market capitalization of $25.25 billion and a P/E ratio of 58.98. The stock’s 50 day moving average price is $160.28 and its 200-day moving average price is $151.12.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.13. The firm earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.80 EPS. Equities research analysts expect that Illumina Inc. will post $3.53 EPS for the current fiscal year.
In related news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total value of $3,459,800.00. Following the completion of the transaction, the director now owns 508,061 shares in the company, valued at approximately $87,889,472.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roy A. Whitfield sold 3,800 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $140.44, for a total transaction of $533,672.00. Following the completion of the transaction, the director now owns 6,653 shares of the company’s stock, valued at approximately $934,347.32. The disclosure for this sale can be found here.
A number of hedge funds and institutional investors recently bought and sold shares of the company. I.G. Investment Management LTD. boosted its position in Illumina by 0.8% in the fourth quarter. I.G. Investment Management LTD. now owns 49,382 shares of the life sciences company’s stock valued at $9,479,000 after buying an additional 414 shares during the period. State of Tennessee Treasury Department bought a new position in Illumina during the fourth quarter valued at $18,274,000. Finally, Schwab Charles Investment Management Inc. boosted its position in Illumina by 103.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 382,838 shares of the life sciences company’s stock valued at $73,484,000 after buying an additional 194,250 shares during the period.
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.